News
-
Vectura will license dry powder formulation technology to GlaxoSmithKline for use in respiratory products for up to £20 million. The deal is for worldwide rights and is non-exclusive. Read the company’s press release. Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 30: RespireX 2027, Boston, MA, USA